Saturday, September 5, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Ares Commercial Real Estate Downgraded to Underperform

Elaine Mendonca by Elaine Mendonca
March 4, 2024
in Breaking News
0
Finance_ Stock Charts (2)
0
SHARES
35
VIEWS
Share on FacebookShare on Twitter

On March 4, 2024, Ares Commercial Real Estate (NYSE:ACRE) faced a downgrade from Buy to Underperform by B of A Securities analyst Eric Dray. The price target was also reduced from $11 to $7. Concerns about declining asset values in the commercial real estate sector, especially impacting ACRE’s office properties and multifamily markets, led to this decision. The company’s financial situation has been negatively affected by decreasing property values, potential credit losses, and challenges in refinancing loans maturing in 2024 and 2025. Despite offering a high yield and having a strong investment platform, the current risks associated with ACRE outweigh the potential rewards.

Ares Commercial Real Estate Corporation (ACRE) Stock Analysis and Performance Review – March 4, 2024

On March 4, 2024, Ares Commercial Real Estate Corporation (ACRE) saw some interesting movements in its stock performance. ACRE is currently trading near the bottom of its 52-week range and below its 200-day simple moving average, indicating possible downward pressure.

Despite this, ACRE saw a positive price change on March 4th, with shares increasing by $0.22 (2.92%) to close at $7.76. However, the stock dropped by $0.16 in pre-market trading, suggesting volatility.

Investors and analysts will monitor ACRE’s performance to see if the positive momentum can be sustained. Stock prices can fluctuate, so it will be interesting to see how ACRE performs in the coming days. Conducting research and consulting with a financial advisor before making investment decisions is recommended.

ACRE Stock Performance Review: Mixed Results for March 4, 2024

On March 4, 2024, ACRE stock showed mixed performances based on the latest financial data provided by CNN Money. The company reported a total revenue of $192.08 million for the past year, which represents an 11.13% increase compared to the previous year. However, the total revenue remained flat at $47.51 million for the last quarter.

In terms of net income, ACRE reported a net loss of $38.87 million for the past year, which is a significant decrease of 230.49% compared to the previous year. On the other hand, the net loss slightly improved to $39.41 million for the last quarter, showing a 0.0% increase compared to the previous quarter.

Earnings per share (EPS) for ACRE also showed a negative trend, with a reported EPS of -$0.72 for the past year, representing a decrease of 225.31% compared to the previous year. The EPS remained the same at -$0.73 for the last quarter, showing no improvement compared to the previous quarter.

Overall, the financial performance of ACRE stock on March 4, 2024, reflects a mixed picture. Investors may want to closely monitor the company’s financial performance and future outlook to make informed decisions about investing in ACRE stock.

Tags: ACRE
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Neurotechnology

Apple Unveils New MacBook Air Models with M3 Chip and Impressive Features

Biopharmaceutical

Groundbreaking Results of Nanobody Sonelokimab in Treating Hidradenitis Suppurativa

Digital platforms

Auddias Strategic Acquisition Plan Targeting Growth and Revenue Expansion

Recommended

Hims & Hers Health Registered (A) Stock

Leadership Moves and Market Jitters at Hims & Hers

11 months ago
FALLBACK Stock

German Court Rules AI Detectors Alone Cannot Prove Cheating, as Firms and Job Seekers Navigate New Landscape

2 months ago

Vontobel Holding Ltd. Reduces Holdings in Ultragenyx Pharmaceutical Inc., Raises Questions about Company’s Financial Performance

3 years ago
Thyssenkrupp Stock

Major Fund Manager Amundi Increases Stake in Thyssenkrupp Amid Share Price Weakness

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly FALLBACK Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Netflix Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics XRP
No Result
View All Result

Highlights

Rheinmetall’s Confidence Crisis: A Leadership Question Overshadows Record Order Books

VanEck’s €9.5bn Dividend ETF Heads Into Payout Day With Shares Virtually Pinned to Their Peak

TKMS: A 40 Billion Euro Question Overshadows a Shipyard at Peak Output

Plug Power’s Cash-Burn Clock Is Ticking Louder Than Any Analyst Price Target

SAP’s Quiet Confidence: Buyback Persistence Meets an Analyst Paradox

SK Hynix’s $29 Billion Confidence Bet Faces Its November Reckoning

Trending

Siemens Energy Stock
Analysis

Siemens Energy’s Breakup Blueprint Takes Centre Stage as Analysts Circle a Narrow Target Range

by Jackson Burston
September 5, 2026
0

The machinery of corporate separation rarely moves at headline speed, but Siemens Energy's latest manoeuvre has given...

BASF Stock

BASF’s Balancing Act: A Texas Patent Battle With Apple Meets a Cooling Analyst View at Home

September 5, 2026
Commerzbank Stock

Commerzbank’s September 14 Test: A Frankfurt-Milan-Berlin Triangle Nears Its Moment of Truth

September 5, 2026
Rheinmetall Stock

Rheinmetall’s Confidence Crisis: A Leadership Question Overshadows Record Order Books

September 5, 2026
VanEck Morningstar Developed Markets Dividend Leaders UCITS ETF Stock

VanEck’s €9.5bn Dividend ETF Heads Into Payout Day With Shares Virtually Pinned to Their Peak

September 5, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Siemens Energy’s Breakup Blueprint Takes Centre Stage as Analysts Circle a Narrow Target Range
  • BASF’s Balancing Act: A Texas Patent Battle With Apple Meets a Cooling Analyst View at Home
  • Commerzbank’s September 14 Test: A Frankfurt-Milan-Berlin Triangle Nears Its Moment of Truth

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com